{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:36:09Z","timestamp":1792064169944,"version":"4.4.0"},"reference-count":116,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0211942","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T13:44:42Z","timestamp":1551275082000},"page":"e0211942","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":37,"title":["Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4053-2445","authenticated-orcid":true,"given":"Nancy F.","family":"Olivieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Sabouhanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9697-9211","authenticated-orcid":true,"given":"Brenda L.","family":"Gallie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"issue":"26","key":"ref1","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJM197606242942603","article-title":"Reassessment of the use of desferrioxamine B in iron overload","volume":"294","author":"RD Propper","year":"1976","journal-title":"N Engl J Med"},{"key":"ref2","first-page":"103","article-title":"The thalassemias. Methods in hematology","volume":"6","author":"MJ Pippard","year":"1983"},{"issue":"25","key":"ref3","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM198506203122503","article-title":"Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major","volume":"312","author":"L Wolfe","year":"1985","journal-title":"N Engl J Med"},{"issue":"8653","key":"ref4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(89)90264-X","article-title":"Survival and causes of death in thalassaemia major","volume":"2","author":"MG Zurlo","year":"1989","journal-title":"Lancet"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM199409013310902","article-title":"Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major","volume":"331","author":"GM Brittenham","year":"1994","journal-title":"N Engl J Med"},{"issue":"9","key":"ref6","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199409013310903","article-title":"Survival in medically treated patients with homozygous beta-thalassemia","volume":"331","author":"NF Olivieri","year":"1994","journal-title":"N Eng J Med"},{"issue":"10","key":"ref7","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"C Borgna-Pignatti","year":"2004","journal-title":"Haematologica"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJM200008033430503","article-title":"Hepatic iron concentration and total body iron stores in thalassemia major","volume":"343","author":"E Angelucci","year":"2000","journal-title":"N Engl J Med"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","article-title":"Iron-chelating therapy and the treatment of thalassemia","volume":"89","author":"NF Olivieri","year":"1997","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199808133390701","article-title":"Long-term safety and effectiveness of iron chelation therapy with deferiprone for thalasemia major.","volume":"339","author":"NF Olivieri","year":"1998","journal-title":"N Eng J Med"},{"key":"ref11","author":"J Thompson","year":"2001"},{"issue":"17","key":"ref12","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJMsb020394","article-title":"Academic freedom in clinical research","volume":"347","author":"DG Nathan","year":"2002","journal-title":"N Engl J Med"},{"key":"ref13","unstructured":"Pazdur R. Complete Response to Application for Ferriprox. OTHER ACTION LETTERS. CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 021825Orig1s000. November 30, 2009."},{"key":"ref14","unstructured":"Farrell AT. Summary Review of Ferriprox. Application number: 021825Orig1s000. Center for Drug Evaluation and Research. 2011."},{"issue":"8","key":"ref15","article-title":"Oral deferiprone for iron chelation in people with thalassaemia","author":"SA Fisher","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"ref16","unstructured":"Ward R, Yeo E. Letter to FDA in support of Ferriprox, New Drug Application 021825 http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/UCM271676.pdf2011<\/ext-link>."},{"key":"ref17","unstructured":"Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada. Ethical Conduct for Research Involving Humans 2014. Available from: http:\/\/www.pre.ethics.gc.ca\/pdf\/eng\/tcps2-2014\/TCPS_2_FINAL_Web.pdf<\/ext-link>."},{"issue":"14","key":"ref18","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJM199504063321404","article-title":"Iron-chelation therapy with oral deferiprone in patients with thalassemia major","volume":"332","author":"NF Olivieri","year":"1995","journal-title":"N Engl J Med"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMct1004810","article-title":"Iron-chelating therapy for transfusional iron overload","volume":"364","author":"GM Brittenham","year":"2011","journal-title":"N Eng J Med"},{"key":"ref20","unstructured":"Monograph F. Ferriprox Drug Monograph 2011 [cited 2018 6 April]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021825lbl.pdf<\/ext-link>."},{"key":"ref21","unstructured":"University Health Network Clinical Guidelines 2012. UHN Red Blood Cell Disorders (RBCD) Program2012 6 April 2018:[75\u20136 pp.]. Available from: https:\/\/guides.library.utoronto.ca\/c.php?g=250874&p=1672175<\/ext-link>; https:\/\/guides.library.utoronto.ca\/ld.php?content_id<\/ext-link> = 10044946."},{"key":"ref22","article-title":"Guidance Document for Industry and Practitioners\u2014Special Access Programme for Drugs","author":"H. Canada","year":"2008","journal-title":"Guidance Document for Industry and Practitioners\u2014Special Access Programme for Drugs"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199808133390701","article-title":"Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major","volume":"339","author":"NF Olivieri","year":"1998","journal-title":"N Engl J Med"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1182\/blood-2002-10-3173","article-title":"Deferiprone and hepatic fibrosis","volume":"101","author":"GM Brittenham","year":"2003","journal-title":"Blood"},{"issue":"9","key":"ref25","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis","volume":"107","author":"DJ Pennell","year":"2006","journal-title":"Blood"},{"key":"ref26","article-title":"Complete Response to Application for Ferriprox","author":"R. Pazdur","year":"2009","journal-title":"Complete Response to Application for Ferriprox"},{"issue":"9","key":"ref27","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/blood-2006-02-002394","article-title":"Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions","volume":"107","author":"EJ Neufeld","year":"2006","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/asheducation-2011.1.451","article-title":"Real-world use of iron chelators","author":"JL Kwiatkowski","year":"2011","journal-title":"Hematol-Am Soc Hematol Educ Program"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2147\/DDDT.S79458","article-title":"Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes","volume":"10","author":"CN Kontoghiorghes","year":"2016","journal-title":"Drug Design Development and Therapy"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/blood-2011-04-344507","article-title":"Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort","volume":"119","author":"JL Kwiatkowski","year":"2012","journal-title":"Blood"},{"key":"ref31","first-page":"435683","article-title":"The management of iron chelation therapy: preliminary data from a national registry of thalassaemic patients","author":"A Ceci","year":"2011","journal-title":"Anemia"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3324\/haematol.2017.176065","article-title":"Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study","volume":"103","author":"S Botzenhardt","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"ref33","first-page":"297","article-title":"Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major","volume":"26","author":"N Waheed","year":"2014","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"ref34","first-page":"223","article-title":"Seventh Cooley's Anemia Symposium","volume":"850","author":"A Cohen","year":"1998"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/1574886310666150930113957","article-title":"Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia","volume":"11","author":"S Botzenhardt","year":"2016","journal-title":"Curr Drug Saf"},{"issue":"9","key":"ref36","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/pbc.25533","article-title":"The deferiprone and deferasirox combination is efficacious in iron overloaded patients with beta-thalassemia major: A prospective, single center, open-label study","volume":"62","author":"S Totadri","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000363210","article-title":"Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with beta-thalassemia: 3-year experience","volume":"133","author":"D Songdej","year":"2015","journal-title":"Acta Haematol"},{"issue":"Suppl 1","key":"ref38","first-page":"264a","article-title":"Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO)","volume":"90","author":"NF Olivieri","year":"1997","journal-title":"Blood"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.beha.2004.08.026","article-title":"Deferiprone therapy for transfusional iron overload","volume":"18","author":"AV Hoffbrand","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/ehm.10.74","article-title":"Iron chelation in thalassemia: time to reconsider our comfort zones","volume":"4","author":"V Berdoukas","year":"2011","journal-title":"Expert review of hematology"},{"issue":"10","key":"ref41","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1182\/blood-2014-01-548552","article-title":"Bad liver and a broken heart","volume":"123","author":"TD Coates","year":"2014","journal-title":"Blood"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2141.1992.tb06445.x","article-title":"Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion-dependent thalassaemia: Indian trial","volume":"82","author":"MB Agarwal","year":"1992","journal-title":"British Journal Of Haematology"},{"issue":"3","key":"ref43","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/blood.V80.3.593.593","article-title":"Efficacy and possible adverse effects of the oral iron chelator 1,2- dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major","volume":"80","author":"FN al-Refaie","year":"1992","journal-title":"Blood"},{"issue":"1","key":"ref44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/blood.V91.1.295","article-title":"Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients","volume":"91","author":"AV Hoffbrand","year":"1998","journal-title":"Blood"},{"issue":"3","key":"ref45","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.1998.00725.x","article-title":"Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients","volume":"101","author":"P Tondury","year":"1998","journal-title":"British Journal Of Haematology"},{"key":"ref46","first-page":"496","article-title":"Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia","volume":"83","author":"P Mazza","year":"1998","journal-title":"Haematologica"},{"issue":"2","key":"ref47","first-page":"115","article-title":"Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).","volume":"85","author":"Y Rombos","year":"2000","journal-title":"Haematologica"},{"issue":"2","key":"ref48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4038\/cmj.v45i2.8005","article-title":"A trial of deferiprone in transfusion-dependent iron overloaded children","volume":"45","author":"GN Lucas","year":"2000","journal-title":"Ceylon Med J"},{"issue":"3","key":"ref49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0955-3886(00)00092-8","article-title":"The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1)","volume":"23","author":"V Berdoukas","year":"2000","journal-title":"Transfus Sci"},{"issue":"2","key":"ref50","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2141.2000.01866.x","article-title":"Safety profile of the oral iron chelator deferiprone: a multicentre study","volume":"108","author":"A Cohen","year":"2000","journal-title":"British Journal Of Haematology"},{"issue":"4","key":"ref51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4038\/cmj.v47i4.3413","article-title":"Experience with the oral iron chelator deferiprone in transfusion-dependent children","volume":"47","author":"GN Lucas","year":"2002","journal-title":"Ceylon Medical Journal"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-2141.2002.03554.x","article-title":"The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients","volume":"118","author":"A Ceci","year":"2002","journal-title":"British Journal Of Haematology"},{"issue":"2","key":"ref53","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/bcmd.2002.0510","article-title":"Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial","volume":"28","author":"A Maggio","year":"2002","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"ref54","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1034\/j.1600-0609.2003.00071.x","article-title":"Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan","volume":"70","author":"CT Peng","year":"2003","journal-title":"Eur J Haematol"},{"issue":"2","key":"ref55","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1081\/HEM-120021538","article-title":"Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with deferoxamine or deferiprone during a randomized multicenter prospective clinical study","volume":"27","author":"M Galia","year":"2003","journal-title":"Hemoglobin"},{"issue":"5","key":"ref56","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","article-title":"Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone","volume":"102","author":"AR Cohen","year":"2003","journal-title":"Blood"},{"key":"ref57","first-page":"21","article-title":"Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children","volume":"41","author":"SR Gomber S","year":"2004","journal-title":"Ind Pediatr"},{"issue":"3","key":"ref58","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF02724272","article-title":"Deferiprone, efficacy and safety","volume":"71","author":"VP Choudhry","year":"2004","journal-title":"Ind J Pediatr"},{"issue":"4","key":"ref59","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000081268","article-title":"Five-year trial of deferiprone chelation therapy in thalassaemia major patients","volume":"112","author":"A Taher","year":"2004","journal-title":"Acta Haematol"},{"issue":"1","key":"ref60","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/03630260500455581","article-title":"Deferiprone or deferoxamine vs combination therapy in patients with beta-thalassemia major: A case study in Taiwan","volume":"30","author":"CT Peng","year":"2006","journal-title":"Hemoglobin"},{"issue":"2","key":"ref61","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/03630260600642617","article-title":"A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong","volume":"30","author":"SY Ha","year":"2006","journal-title":"Hemoglobin"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH3013.x","article-title":"Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with b-thalassaemia major: comparison between different chelation regimens","volume":"78","author":"A Christoforidis","year":"2006","journal-title":"Eur J Haematol"},{"issue":"2","key":"ref63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/03630260600642518","article-title":"Effect of deferiprone on liver iron overload and fibrosis in hepatitis C virus-infected thalassemia","volume":"30","author":"AC Chen","year":"2006","journal-title":"Hemoglobin"},{"issue":"12","key":"ref64","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.11414","article-title":"A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major","volume":"92","author":"Y Aydinok","year":"2007","journal-title":"Haematologica"},{"issue":"7","key":"ref65","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00277-008-0471-2","article-title":"Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience","volume":"87","author":"A El-Beshlawy","year":"2008","journal-title":"Ann Hematol"},{"issue":"3","key":"ref66","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bcmd.2009.01.002","article-title":"Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies","volume":"42","author":"A Maggio","year":"2009","journal-title":"Blood Cells Molecules and Diseases"},{"issue":"2","key":"ref67","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2009.07609.x","article-title":"Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial","volume":"145","author":"A Maggio","year":"2009","journal-title":"British Journal Of Haematology"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5045\/kjh.2010.45.1.58","article-title":"Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients","volume":"45","author":"S Won","year":"2010","journal-title":"Korean J Hematol"},{"issue":"5","key":"ref69","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1600-0609.2010.01499.x","article-title":"Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone\/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.","volume":"85","author":"A Kolnagou","year":"2010","journal-title":"Eur J Haematology."},{"issue":"11","key":"ref70","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1440-1754.2011.02031.x","article-title":"Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia","volume":"47","author":"SS Jamuar","year":"2011","journal-title":"J Paediatrics and Child Health"},{"issue":"1","key":"ref71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.2009.019042","article-title":"Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging","volume":"96","author":"A Pepe","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"ref72","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/03630269.2011.570674","article-title":"Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: Main findings and clinical follow-up of a large multicenter randomized clinical trial in beta-thalassemia major patients","volume":"35","author":"GR Pantalone","year":"2011","journal-title":"Hemoglobin"},{"issue":"9","key":"ref73","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00277-012-1480-8","article-title":"Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients","volume":"91","author":"E Cassinerio","year":"2012","journal-title":"Ann Hematol"},{"issue":"4","key":"ref74","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ajh.23386","article-title":"Deferiprone monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study from Thailand","volume":"88","author":"V Viprakasit","year":"2013","journal-title":"Am J Hematol"},{"issue":"9","key":"ref75","first-page":"1241","article-title":"A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia","volume":"91","author":"R Galanello","year":"2006","journal-title":"Haematologica"},{"issue":"14","key":"ref76","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance","volume":"115","author":"MA Tanner","year":"2007","journal-title":"Circulation"},{"issue":"1\u20132","key":"ref77","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/03630260701680474","article-title":"Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia","volume":"32","author":"M Tsironi","year":"2008","journal-title":"Hemoglobin"},{"issue":"5","key":"ref78","first-page":"327","article-title":"Hepatic iron concentration and total body iron stores in thalassemia major.[comment][erratum appears in N Engl J Med 2000 Dec 7;343(23):1740]","volume":"343","author":"E Angelucci","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"ref79","first-page":"107","article-title":"Tenth Cooley's Anemia Symposium","volume":"1368","author":"JL Kwiatkowski","year":"2016"},{"issue":"3","key":"ref80","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2141.2009.07970.x","article-title":"Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major","volume":"148","author":"K Farmaki","year":"2010","journal-title":"British Journal Of Haematology"},{"issue":"1","key":"ref81","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1532-429X-11-20","article-title":"The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.","volume":"11","author":"V Berdoukas","year":"2009","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1\u20132","key":"ref82","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/03630260701727085","article-title":"Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine\/deferiprone combination. identification of effective chelation therapy protocols","volume":"32","author":"A Kolnagou","year":"2008","journal-title":"Hemoglobin"},{"issue":"5","key":"ref83","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2004.04946.x","article-title":"Purging iron from the heart","volume":"125","author":"C Hershko","year":"2004","journal-title":"British Journal Of Haematology"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2008-04-148767","article-title":"Longitudinal analysis of heart and liver iron in thalassemia major","volume":"112","author":"LJ Noetzli","year":"2008","journal-title":"Blood"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1532-429X-15-38","article-title":"Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone","volume":"15","author":"JB Porter","year":"2013","journal-title":"J Cardiov Magn Reson"},{"issue":"2\u20133","key":"ref86","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000039759","article-title":"Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting","volume":"104","author":"GC Del Vecchio","year":"2000","journal-title":"Acta Haematol"},{"issue":"2","key":"ref87","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/03630260600642534","article-title":"Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients","volume":"30","author":"SF Wu","year":"2006","journal-title":"Hemoglobin"},{"issue":"2","key":"ref88","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcmd.2013.04.002","article-title":"Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major","volume":"51","author":"A Filosa","year":"2013","journal-title":"Blood Cells Molecules and Diseases"},{"issue":"6","key":"ref89","first-page":"1959","article-title":"Effect of combined versus monotherapy with deferoxamine and deferiprone in iron overloaded thalassemia patients: a randomized clinical trial","volume":"4","author":"S Hejazi","year":"2016","journal-title":"Int J Pediatr"},{"issue":"2","key":"ref90","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1046\/j.1365-2141.1998.01002.x","article-title":"Combined therapy with deferiprone and desferrioxamine","volume":"103","author":"B Wonke","year":"1998","journal-title":"British Journal Of Haematology"},{"issue":"1","key":"ref91","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1046\/j.1365-2141.1999.01560.x","article-title":"Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major","volume":"106","author":"Y Aydinok","year":"1999","journal-title":"British Journal Of Haematology"},{"issue":"4","key":"ref92","first-page":"493","article-title":"Combined oral and parenteral iron chelation in beta thalassaemia major","volume":"55","author":"K Balveer","year":"2000","journal-title":"Med J Malaysia"},{"issue":"1","key":"ref93","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.04240.x","article-title":"Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients","volume":"121","author":"FH Mourad","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"7","key":"ref94","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00043426-200407000-00011","article-title":"Combined therapy with desferrioxamine and deferiprone: A new protocol for iron chelation in Thalassemia.","volume":"26","author":"E D'Angelo","year":"2004","journal-title":"Journal of Pediatric Hematology Oncology"},{"issue":"6","key":"ref95","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/sj.thj.6200550","article-title":"Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone","volume":"5","author":"V Alymara","year":"2004","journal-title":"Hematology Journal"},{"issue":"1","key":"ref96","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bcmd.2005.11.002","article-title":"Iron chelation treatment with combined therapy with deferiprone and deferioxamine: A 12-month trial","volume":"36","author":"A Kattamis","year":"2006","journal-title":"Blood Cells Molecules and Diseases"},{"issue":"1","key":"ref97","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-0609.2010.01447.x","article-title":"Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study","volume":"85","author":"P Ricchi","year":"2010","journal-title":"Eur J Haematol"},{"issue":"6","key":"ref98","first-page":"655","article-title":"Comparison between deferoxamine and combined therapy with deferoxamine and deferiprone in iron overloaded thalassemia patients","volume":"12","author":"A Tamaddoni","year":"2010","journal-title":"Iranian Red Crescent Medical Journal"},{"issue":"2","key":"ref99","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bcmd.2010.05.005","article-title":"Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone","volume":"45","author":"ME Lai","year":"2010","journal-title":"Blood Cells Molecules and Diseases"},{"issue":"1","key":"ref100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1658-3612(10)70121-9","article-title":"Experience with combination therapy of deferiprone and desferrioxamine in \u03b2-thalassemia major patients with iron overload at Maternity and Children Hospital, Saudi Arabia.","volume":"5","author":"ZM Al Hawsawi","year":"2010","journal-title":"Journal of Taibah University Medical Sciences"},{"issue":"3","key":"ref101","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1179\/102453312X13376952196610","article-title":"The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients","volume":"17","author":"N Mirbehbahani","year":"2012","journal-title":"Hematology"},{"issue":"3","key":"ref102","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bcmd.2013.06.001","article-title":"Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment","volume":"51","author":"F Danjou","year":"2013","journal-title":"Blood Cells Molecules and Diseases"},{"issue":"1","key":"ref103","first-page":"70","article-title":"Comparative efficacy of deferiprone, deferoxamine and combination of deferiprone and deferoxamine on serum ferritin value in beta-thalassemia patients","volume":"4","author":"N Mirbehbahani","year":"2015","journal-title":"J Krishna Inst Med Sci Univ"},{"issue":"10","key":"ref104","first-page":"1309","article-title":"Combined therapy with deferiprone and desferrioxamine in thalassemia major","volume":"90","author":"R Origa","year":"2005","journal-title":"Haematologica"},{"issue":"5","key":"ref105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00277-005-0075-z","article-title":"Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload","volume":"85","author":"S Daar","year":"2006","journal-title":"Ann Hematol"},{"issue":"6","key":"ref106","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/10245330701521614","article-title":"Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.","volume":"12","author":"N. Abdelrazik","year":"2007","journal-title":"Hematology"},{"issue":"5","key":"ref107","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF02983992","article-title":"Comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2*magnetic resonance imaging in patients with beta-thalassemia major","volume":"86","author":"V Perifanis","year":"2007","journal-title":"International journal of hematology"},{"issue":"3","key":"ref108","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/03630269.2010.485120","article-title":"Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients","volume":"34","author":"D Tsiapras","year":"2010","journal-title":"Hemoglobin"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1532-429X-14-8","article-title":"Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major","volume":"14","author":"F Alpendurada","year":"2012","journal-title":"J Cardiovasc Magn Reson"},{"issue":"5","key":"ref110","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood-2002-01-0306","article-title":"Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia","volume":"100","author":"IR Wanless","year":"2002","journal-title":"Blood"},{"issue":"2","key":"ref111","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1586\/17474086.2016.1126176","article-title":"Clinical monitoring and management of complications related to chelation therapy in patients with beta-thalassemia","volume":"9","author":"AN Saliba","year":"2016","journal-title":"Expert review of hematology"},{"key":"ref112","first-page":"570","article-title":"The International Study Group on Oral Iron Chelators: Results of long-term deferiprone (L1) therapy","volume":"93","author":"C Hershko","year":"1996","journal-title":"British Journal Of Haematology"},{"issue":"2","key":"ref113","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2141.2003.04412.x","article-title":"Clinical trial of deferiprone iron chelation therapy in B-thalassaemia\/haemoglobin E patients in Thailand","volume":"122","author":"P Pootrakul","year":"2003","journal-title":"British Journal Of Haematology"},{"issue":"3","key":"ref114","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3109\/03630269.2010.485890","article-title":"Manitenance of normal body range iron store level for up to 4.5 years in Thalassemia Major patients using deferiprone monotherapy","volume":"34","author":"A Kolnagou","year":"2010","journal-title":"Hemoglobin"},{"issue":"3","key":"ref115","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1503\/cmaj.1040752","article-title":"Liver enzyme alteration: a guide for clinicians","volume":"172","author":"EG Giannini","year":"2005","journal-title":"Canadian Medical Association Journal"},{"issue":"Suppl 1","key":"ref116","doi-asserted-by":"crossref","first-page":"3185a","DOI":"10.1182\/blood.V118.21.3185.3185","article-title":"Single centre, North American experience with compassionate use of deferiprone in patients with beta-thalassemia major","volume":"118","author":"F Miscevic","year":"2011","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0214005","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0211942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T01:21:48Z","timestamp":1721006508000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0211942"}},"subtitle":[],"editor":[{"given":"Godfrey","family":"Biemba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":116,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0211942","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,27]]}}}